Dogwood Therapeutics, Inc. · NASDAQ:DWTX

Dogwood Therapeutics — Virios Therapeutics — Corporate Update (March 2022)

20 slides from Dogwood Therapeutics's corporate update, Mar 1, 2022

  1. Slide 1: New Scientific Paradigm Exploring Herpes Virus Activation as Potential Underlying Cause of Fibromyalgia, Long COVID

    HSV-1virus Virios Therapeutics, Inc. Nasdaq: VIRINew Scientific Paradigm ExploringHerpes Virus Activation asPotential Underlying Cause of Fibromyalgia, Long COVIDand Other Chronic ConditionsCorporate Update Q1, 20211

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements2Statements in this presentation contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in thispresentation may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,”

  3. Slide 3: Virios Therapeutics Summary

    Virios Therapeutics Summary3Nasdaq: VIRIFocused on Two Significant Commercial Opportunities: The Large, Dissatisfied Fibromyalgia(FM) Market: 2%-8% of the PopulationLong COVID, a Rapidly Emerging Unmet Need: Impacts an Estimated 100M Post-COVID Patients WorldwideOral IMC-1 (famciclovir + celecoxib

  4. Slide 4: Proven Leadership Team with Extensive Experience in Drug Development and Commercialization

    Proven Leadership Team with Extensive Experience in Drug Development and Commercialization 4 Pharma Brand Development & Commercialization Experience Includes Management of: Greg DuncanChairman & CEO R. Michael Gendreau MD, PhD CMO Ralph GrosswaldVP of Operations Angela WalshSVP of FinanceEXECUTIVE T

  5. Slide 5: Discovery Implicates Dormant Herpes Virus Reactivation Triggers Immune Response, Manifestation of FM and Long COVID

    Discovery Implicates Dormant Herpes Virus Reactivation Triggers Immune Response, Manifestation of FM and Long COVID 5Source: P.A. Bond, Medical Hypotheses, 1993,; R. A Vere Hodge and Y.-G. Cheng, Antiviral Chemistry & Chemotherapy, 1993; Kaufman et al, IOVS, 2005;Liu Y, et al, Scientific World Journ

  6. Slide 6: Synergistic Antiviral Mechanism Serves as the Basis for Proposed Fibromyalgia and Long COVID Treatment Effect

    Synergistic Antiviral Mechanism Serves as the Basis for Proposed Fibromyalgia and Long COVID Treatment Effect 6 Herpes Virus Conversion Back to a Dormant State, Enables Immune Response to Reset, ProvideClinical Benefits Source: P.A. Bond, Medical Hypotheses, 1993,; R. A Vere Hodgeand Y.-G. Cheng, An

  7. Slide 7: Fibromyalgia Disease Overview

    •FM is a Chronic Disease that Affects up to 8% of the US Population•Hallmark Characteristics are Widespread Chronic Pain and Severe Fatigue •Symptoms Present for ≥ 3 Months•Other Symptoms May Include GI, Sleep, Mood Disorder and Headache Devastating Impact•Patients with FM> 3x Risk of Committing Sui

  8. Slide 8: The Fibromyalgia Market is Large and Poised for Growth If Better Therapeutic Options Emerge

    The Fibromyalgia Market is Large and Poised for Growth IFBetter Therapeutic Options Emerge8Significant Growth Potential Still Exists 10.0M3.6M2.0MTotal FM PatientsDiagnosedPatientsTreated Patients 36% Diagnostic Rate 20% Treatment Rate Source: National Fibromyalgia and Chronic Pain Association 2021;

  9. Slide 9: IMC-1: Completed Phase 2a Clinical Proof of Concept Trial

    Week12345678910111213141516IMC-1 N = 69PlaceboN = 749Design Summary:•Randomized, Double-blind, Multi-center, Placebo-controlled •IMC-1 (famciclovir + celecoxib) vs Placebo, Dosed Twice Daily•Diagnosis of Fibromyalgia Using 2010 American College of RheumatologyIMC-1: Completed Phase 2a Clinical Proof

  10. Slide 10: IMC-1 Demonstrated Statistically Significant Reduction in Pain in Phase 2a Clinical Trial

    10 IMC-1 Demonstrated Statistically Significant Reduction in Pain in Phase 2a Clinical TrialSource: Pridgen et al, Journal of Pain Research, 2017, Virios Therapeutics, Inc. Nasdaq: VIRI

  11. Slide 11: IMC-1 Treatment Resulted in Consistent Treatment Effects and Tolerability Better Than Placebo at 16 Weeks

    IMC-1 Treatment Resulted inConsistent Treatment Effects and Tolerability Better Than Placebo at 16 Weeks11 Secondary EndpointsP ValuePROMIS(NIH) Fatigue Assessmentp=0.001PGIC -Patient’s Global Impression of ChangeP=0.040FIQ-R-Revised Fibromyalgia Impact Questionnaire Total Score p=0.002FIQ-R –Functi

  12. Slide 12: IMC-1 Phase 2b Design Using Optimized Dosage, 350+ Patients Presently Enrolled

    IMC-1 Phase 2b Design Conducted Using Optimized IMC-1 Dosage, 350+ Patients Presently Enrolled 12 ‘21‘22Q2Q3Q4Q1Q2Q3Q4Study EnrollmentTop Line ResultsFDA End P2 Mtg Females Aged 18-65 (n = 400+) IMC-1 single tablet (famciclovir 675mg + 180 mg celecoxib) dosed b.i.d. Placebo dosed b.i.d. Week 6VisitW

  13. Slide 13: Long COVID Prevalence is Significant and Represents an Emerging Unmet Medical Need

    Long COVID Prevalence is Significant and Represents an Emerging Unmet Medical Need13The mechanisms by which COVID-19 causes lingering symptoms in survivors are not fully understood but are hypothesized to result from: •Immune-system dysregulation triggered by the COVID-19 virus, including increased

  14. Slide 14: Common Symptoms Noted In Post-COVID Patients

    Common Symptoms Noted In Post-COVID Patients14Source: Garrigues et al. Infect.2020;Carifi, et. al. JAMA. 2020;J Gold, Pathogens, 2021; F Bai, Clinical Microbial Infections, 2021Fatigue is Consistently the Most Common Symptom Amongst Long COVID PatientsNasdaq: VIRI Fatigue 55%Difficulty breathing

  15. Slide 15: IMC-2 Exploratory Long COVID Study

    IMC-2 Exploratory Long COVID Study15Nasdaq: VIRI ‘22‘23Q1Q2Q3Q4Q1Q2EnrollmentTop Line Results Females Aged 18-65 IMC-2 (valacyclovir 1.25g + celecoxib 200 mg) dosed b.i.d. Standard of care control Week 6VisitWeek 10VisitWeek 14Visit Baseline Exploratory Endpoints Include : Fatigue, pain, sleep, anxi

  16. Slide 16: Combination Antiviral Research Pipeline Provides Rich Milestone Progression

    Combination Antiviral Research Pipeline Provides Rich Milestone Progression16Nasdaq: VIRI Pipeline CandidatesDiseasePre-ClinicalPhase 1/ ExploratoryPhase 2Phase 3IMC-1:(famciclovir + celecoxib)FMPhase 2bIMC-1:(famciclovir + celecoxib)IBSIMC-2: (valacyclovir + celecoxib)Long COVIDExploratory Q2 ‘22 •

  17. Slide 17: Strong IP Portfolio with Issued Patents

    Strong IP Portfolio with 21 Issued Patents17Four IssuedUSIMC-1Patents•Two “CompositionofMatter”Patents•Drug-combinationof famciclovir andcelecoxib•Synergistic combination for total daily dose of famciclovir and celecoxib•Two “Method-of-Use”Patents•Famciclovir+celecoxibforthetreatmentofFM (fibromyalg

  18. Slide 18: Capitalization Table as of December 31, 2021

    Capitalization Table as of December 31, 202118 Exchange/SymbolNasdaq/VIRICommon Shares Outstanding8,330,390Underwriters Warrants (Exercisable at $12.50/share) 172,500Stock Options* (Employees, Directors & Officers)1,041,647Fully Diluted Shares Outstanding9,544,537Management Ownership** on a Fully Di

  19. Slide 19: Virios Therapeutics Summary

    Virios Therapeutics Summary19Nasdaq: VIRIFocused on Two Significant Commercial Opportunities: The Large, Dissatisfied Fibromyalgia(FM) Market: 2%-8% of the PopulationLong COVID, a Rapidly Emerging Unmet Need: Impacts an Estimated 100M Post-COVID Patients WorldwideOral IMC-1 (famciclovir + celecoxi

  20. Slide 20: Thank You!

    HSV-1virus Thank You!For Additional Information, Contact:Kirin Smith: ksmith@pcgadvisory.com or ir@virios.com 20 www.virios.com

Virios Therapeutics — Corporate Update (March 2022) on 6ix